<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119108">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552369</url>
  </required_header>
  <id_info>
    <org_study_id>DMID 11-0073</org_study_id>
    <secondary_id>272201100041C-3-0-1</secondary_id>
    <nct_id>NCT01552369</nct_id>
  </id_info>
  <brief_title>Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients</brief_title>
  <acronym>CAPSIL</acronym>
  <official_title>Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of two different approaches for the prevention of CMV disease in liver
      transplant recipients. The primary purpose is to determine if Preemptive therapy is the same
      or better than Prophylaxis therapy for the prevention of CMV disease in CMV seronegative
      recipients that receive a CMV positive liver transplant. Patients meeting study criteria and
      who have provided informed consent will be randomized within 10 days of transplant to
      receive in an open label design, either antiviral prophylaxis with valganciclovir 900 mg
      orally once daily for 100 days or preemptive therapy (weekly monitoring for asymptomatic CMV
      viremia by plasma PCR) for 100 days with initiation of oral valganciclovir 900mg orally
      twice daily only at onset of CMV viremia and continued until plasma PCR is negative on two
      consecutive weekly PCR tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Prophylaxis versus Preemptive Therapy for Prevention of CMV in High-Risk R-/D+ Liver
      Transplant Recipients ['CAPSIL' Study]

      Population: CMV seronegative recipients (18 years of age or older) of a liver transplant
      from a CMV seropositive donor (R-/D+)

      Phase: IV

      Number of Clinical Sites: 5

      Study Duration: 7 years

      Subject Participation Duration: Until the closure of the study and not to exceed 7 years
      from enrollment.

      Description of Agent or Intervention: Oral Valganciclovir hydrochloride:
      2-[(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)methoxy]-3-hydroxypropyl
      (2S)-2-amino-3-methylbutanoate. Currently marketed as Valcyte Â®.

      The primary objective is to compare prophylaxis versus preemptive therapy using
      valganciclovir for the prevention of CMV disease in R-/D+ liver transplant recipients

      Secondary objectives :To assess the two preventive strategies for:

        -  Clinical outcomes (major bacterial, fungal and non-CMV viral infections, rejection,
           graft loss and mortality)

        -  Hematologic toxicity (assessment of neutropenia and receipt of hematopoietic growth
           factor during study days 1-107)

      Study Design: This is a prospective, randomized, multicenter trial of preemptive therapy vs.
      prophylaxis for prevention of CMV disease in R-D+ liver transplant patients. Patients
      meeting study criteria and who have provided informed consent will be randomized within 10
      days of transplant to receive in an open label design, either antiviral prophylaxis with
      valganciclovir 900 mg orally once daily or preemptive therapy (weekly monitoring for CMV
      viremia by plasma PCR) for 100 days post- randomization with initiation of oral
      valganciclovir 900mg orally twice daily at onset of CMV viremia and continued until plasma
      PCR is negative on two consecutive weekly PCR tests). Valganciclovir dosages will be
      adjusted for renal dysfunction. Study participants will be followed during the intervention
      period (100 days post randomization) and until 12 months post-transplant for CMV disease,
      toxicity, and clinical outcomes (opportunistic infections, rejection, graft loss and
      mortality).

      Estimated Time to Complete Enrollment: Approximately 5.0 years
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of CMV disease</measure>
    <time_frame>One year post enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>One year post enrollment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of late onset CMV diseae</measure>
    <time_frame>After 100 days post-randomization to 1 year</time_frame>
    <description>CMV disease occurring after completion of prophylaxis or monitored CMV viremia testing</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of allograft rejection</measure>
    <time_frame>Randomization to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of graft loss</measure>
    <time_frame>Randomization to 1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of neutropenia</measure>
    <time_frame>Randomization to 107 days post-enrollment</time_frame>
    <description>Absolute neutrophil count &lt;1000</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Cytomegalovirus Disease</condition>
  <arm_group>
    <arm_group_label>Prophylaxis with Valganciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects given 900mg valganciclovir daily for 100 days post transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preemptive Therapy [PET]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects monitored with weekly CMV PCR testing and given 900 mg valganciclovir twice daily only if PCR is positive. Therapy is stopped after 2nd negative PCR test</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preemptive Therapy</intervention_name>
    <description>Subjects monitored for CMV viremia with weekly CMV PCR testing. 900 mg of Valganciclovir given twice daily only after a positive CMV PCR test and stopped after PCR is negative for 2 weeks. Dosages may be adjusted for renal dysfunction</description>
    <arm_group_label>Preemptive Therapy [PET]</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylaxis with Valganciclovir</intervention_name>
    <description>All subjects in this arm are given 900mg valganciclovir daily for 100 days post transplantation. Dosage may be adjusted for renal dysfunction</description>
    <arm_group_label>Prophylaxis with Valganciclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Greater than 18 yrs of age

          -  Negative CMV serology recipient

          -  Positive CMV serology donor

          -  Liver transplant within 10 days

          -  Absolute neutrophil count&gt;1000

          -  Female subjects of childbearing potential must have negative pregnancy test and agree
             to use effective contraception during and for 3 months after receipt of
             valganciclovir

          -  Male subjects, that have not had a vasectomy, must agree to practice barrier method
             of contraception during and for 3 months after receipt of valganciclovir

        Exclusion Criteria:

          -  Enrollment in other investigational drug trials

          -  Hypersensitivity to acyclovir, ganciclovir or valganciclovir

          -  Breast feeding mother

          -  HIV infection

          -  Multiple organ transplant or re-transplantation

          -  Life expectancy of less than 72 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Winston, MD</last_name>
      <phone>310-825-6264</phone>
      <email>dwinston@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Janet Moooney</last_name>
      <phone>310-794-8600</phone>
      <email>JMooney@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Drew Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Health care</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G M Lyon, MD</last_name>
      <phone>404-712-2051</phone>
      <email>Marshall.Lyon@emoryhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Marti Sears</last_name>
      <phone>404-712-5411</phone>
      <email>mhsears@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>G. Marshall Lyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Transplant Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymund Razonable, MD</last_name>
      <phone>507-284-3747</phone>
      <email>razonable.raymund@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristen Cornwell</last_name>
      <phone>507-266-8493</phone>
      <email>Cornwell.kristen@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Raymund Razonable, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda P Silveira, MD</last_name>
      <phone>412-648-6512</phone>
      <email>Silveirafd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Fernanda P Silveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajit Limaye, MD</last_name>
      <phone>206-598-6131</phone>
      <email>Limaye@u.washington.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michaela Kusumi, BS</last_name>
      <phone>206-598-1810</phone>
    </contact_backup>
    <investigator>
      <last_name>Ajit Limaye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 24, 2016</lastchanged_date>
  <firstreceived_date>March 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Nina Singh</investigator_full_name>
    <investigator_title>Professor of Medicine, Transplant Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>liver transplantation</keyword>
  <keyword>CMV disease</keyword>
  <keyword>valgancyclovir</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>preemptive therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
